Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050490 | 0.81 | AOC3 (0.46) | HRH3CYP2D6AOC3 | |
| SCHEMBL17050491 | 0.76 | PIK3CA (0.43) | AOC3 | |
| SCHEMBL8407964 | 0.76 | SMN1; SMN2 (0.56) | SRD5A1 | |
| SCHEMBL28499625 | 0.74 | HRH3 (0.70) | SRD5A1HRH3CYP2D6HRH1SLC6A2 | |
| SCHEMBL11043671 | 0.74 | SRD5A1 (0.54) | SRD5A1HRH3CYP2D6HRH1SLC6A2 | |
| SCHEMBL22432716 | 0.73 | HRH3 (0.60) | SRD5A1HRH3CYP2D6HRH1PDK1 | |
| Hydrochloric Acid SCHEMBL10640696 | 0.73 | SRD5A1 (0.53) | SRD5A1HRH3CYP2D6HRH1SLC6A2 | |
| SCHEMBL9194405 | 0.72 | HRH3 (0.53) | SRD5A1HRH3CYP2D6HRH1ROCK2 | |
| SCHEMBL10636990 | 0.72 | SRD5A1 (0.53) | SRD5A1HRH3CYP2D6HRH1MAOA | |
| SCHEMBL28757282 | 0.72 | HRH3 (0.63) | SRD5A1HRH3CYP2D6HRH1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | SRD5A1 1134/4885HRH3 289/4885CYP2D6 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.